Related Experiment Video
Updated: Jan 24, 2026
Cell Type-specific Gene Expression Profiling in the Mouse Liver
Published on: September 17, 2019
AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses
Chunhua Qin1, Amy G Aslamkhan1, Kara Pearson1
1Department of Safety Assessment and Laboratory Animal Resources.
Abstract:
Aryl hydrocarbon receptor (AhR) activation is associated with carcinogenicity of non-genotoxic AhR-activating carcinogens such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD), and is often observed with drug candidate molecules in development and raises safety concerns. As downstream effectors of AhR signaling, the expression and activity of Cyp1a1 and Cyp1a2 genes are commonly monitored as evidence of AhR activation to inform carcinogenic risk of compounds in question. However, many marketed drugs and phytochemicals are reported to induce these Cyps modestly and are not associated with dioxin-like toxicity or carcinogenicity. We hypothesized that a threshold of AhR activation needs to be surpassed in a sustained manner in order for the dioxin-like toxicity to manifest, and a simple liver gene expression signature based on Cyp1a1 and Cyp1a2 from a short-term rat study could be used to assess AhR activation strength and differentiate tumorigenic dose levels from non-tumorigenic ones. To test this hypothesis, short-term studies were conducted in Wistar Han rats with 2 AhR-activating carcinogens (TCDD and PCB126) at minimally carcinogenic and noncarcinogenic dose levels, and 3 AhR-activating noncarcinogens (omeprazole, mexiletine, and canagliflozin) at the top doses used in their reported 2-year rat carcinogenicity studies. A threshold of AhR activation was identified in rat liver that separated a meaningful "tumorigenic-strength AhR signal" from a statistically significant AhR activation signal that was not associated with dioxin-like carcinogenicity. These studies also confirmed the importance of the sustainability of AhR activation for carcinogenic potential. A sustained activation of AhR above the threshold could thus be used in early pharmaceutical development to identify dose levels of drug candidates expected to exhibit dioxin-like carcinogenic potential.
Insights
Aryl hydrocarbon receptor (AhR) activation strength can predict carcinogenicity. A sustained AhR activation above a specific threshold in rat liver distinguishes tumorigenic from non-tumorigenic dose levels, aiding drug development safety assessments.
Area of Science:
- Toxicology and Pharmacology
- Drug Safety Evaluation
- Carcinogenesis Research
Background:
- Aryl hydrocarbon receptor (AhR) activation is linked to carcinogenicity of certain compounds.
- Monitoring Cyp1a1 and Cyp1a2 gene expression is standard for assessing AhR activation and carcinogenic risk.
- Many compounds induce these genes without causing dioxin-like toxicity, suggesting a need for refined assessment methods.
Purpose of the Study:
- To determine if a threshold of sustained AhR activation exists for dioxin-like toxicity.
- To evaluate if liver gene expression signatures can differentiate tumorigenic from non-tumorigenic doses of AhR-activating compounds.
- To establish a predictive tool for early pharmaceutical development.
Main Methods:
- Short-term rat studies using known AhR-activating carcinogens (TCDD, PCB126) and noncarcinogens (omeprazole, mexiletine, canagliflozin).
- Doses included minimally carcinogenic, noncarcinogenic, and highest used in 2-year studies.
- Analysis of liver gene expression (Cyp1a1, Cyp1a2) to assess AhR activation strength and sustainability.
Main Results:
- Identified a threshold of AhR activation in rat liver that separates tumorigenic from non-tumorigenic signals.
- Confirmed that sustained AhR activation is crucial for dioxin-like carcinogenicity.
- Demonstrated that a "tumorigenic-strength AhR signal" can be differentiated from statistically significant but non-carcinogenic activation.
Conclusions:
- A sustained AhR activation above a defined threshold predicts dioxin-like carcinogenic potential.
- This threshold provides a valuable tool for early identification of safety concerns in drug candidates.
- Refined assessment of AhR activation strength can improve risk evaluation in pharmaceutical development.
Related Concept Videos
01:58Cell Specific Gene Expression
01:58Cell Specific Gene Expression
01:42What is Gene Expression?
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...
01:36What is Gene Expression?
02:35Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
02:51mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability